Global Systemic Psoriasis Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Systemic Psoriasis Therapeutics Market Growth (Status and Outlook) 2023-2029

Psoriasis is an autoimmune skin disease that causes scaling, skin redness and irritation. Psoriasis causes red, scaly patches that are generally found on the elbows, fingernails, scalp, palms, knees, face, feet and inside the mouth. Factors that can trigger psoriasis include infections, heavy alcohol consumption, cold weather, certain medications, smoking, stress and injury to the skin such as bug bite, cut and sever sunburn. The signs and symptoms of psoriasis vary from person to person which includes dry, cracked skin that may bleed, red patches of skin covered with silvery scales, small scaling spots, itching, burning, swollen and stiff joints. Psoriasis may be classified into various types such as plaque psoriasis, scalp psoriasis, pustular psoriasis, psoriatic arthritis, guttate psoriasis, nail psoriasis, erythrodermic psoriasis and inverse psoriasis. Various treatments for psoriasis are oral medication, topical medication and biologics injections. Psoriasis can also be treating by phototherapy treatment which includes ultraviolet light therapy, laser treatment, tanning beds, psoralen +UVA and sunlight treatment. Psoriasis can occur in any part of the body and it is associated with other health conditions such as heart disease, diabetes and depression.

LPI (LP Information)' newest research report, the “Systemic Psoriasis Therapeutics Industry Forecast” looks at past sales and reviews total world Systemic Psoriasis Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Systemic Psoriasis Therapeutics sales for 2023 through 2029. With Systemic Psoriasis Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Systemic Psoriasis Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Systemic Psoriasis Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Systemic Psoriasis Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Systemic Psoriasis Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Systemic Psoriasis Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Systemic Psoriasis Therapeutics.

The global Systemic Psoriasis Therapeutics market size is projected to grow from US$ 11470 million in 2022 to US$ 19420 million in 2029; it is expected to grow at a CAGR of 7.8% from 2023 to 2029.

One trend resulting in the strong growth of this market is the advent of biologics with novel MOA and cell-based strategies. This market is expected to witness the launch of biologic agents that target the disease pathway specifically, including IL-17/IL-17R receptor inhibitors. Drugs such as brodalumab, guselkumab, and tildrakizumab are undergoing Phase III clinical trials.

This report presents a comprehensive overview, market shares, and growth opportunities of Systemic Psoriasis Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Biologics
Small Molecules

Segmentation by application
Mild Psoriasis
Moderate Psoriasis
Severe Psoriasis

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Johnson & Johnson
Celgene
Amgen
Pfizer

Please note: The report will take approximately 2 business days to prepare and deliver.